Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, engages in developing and commercializing products in the therapeutic areas of allergy and respiratory disease. Its specialty pharmaceutical product candidates include the Epinephrine Injection PFS syringe product for use in the emergency treatment of anaphylaxis; APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease; and APC-2000 for the treatment of bronchospasms. The company also has various biotechnology product candidates and technologies, including therapeutic vaccine and cancer product candidates that comprise TeloB-VAX (vaccine), APC-100, APC-200, and APC-300, which are under development for the treatment of prostate cancer. In addition, it operates a 503B drug outsourcing facility that provides prescription medications to patients, physician clinics, hospitals, and surgery centers in the United States. The company is headquartered in San Diego, California.